Tuesday,
January 14, 2003
United
States Patent and Trademark Office
Arlington,
Virginia 22202
Crystal
Square 4, 7th Floor, Room 1
The most recent
quarterly meeting for the Biotechnology and Chemical Pharmaceutical Customer
Partnership was held on October 8, 2002, at the U.S. Patent and Trademark
Office. The Biotechnology and Chemical Pharmaceutical Customer Partnership
is designed and developed to be a forum to share ideas, experiences, and
insights between individual users and the USPTO. The USPTO does
not intend to use these customer partnership groups to arrive at any consensus.
Invitations to participate will indicate that individual opinions are
sought, rather than a group consensus and that the meetings are intended
to be informal in nature and have varying participants. These customer
partnership groups are formed with full recognition of the USPTO’s responsibility
under the Federal Advisory Committee Act (FACA), and that these customer
partnership groups are not established as FACA compliant committees.
We value our customers
in obtaining feedback from individual participants is important in our
efforts to continuously improve the quality of our products and services.
Your willing participation is helpful in providing us with insights and
experiences in this informal process to assist us.
The next meeting of
the US Patent and Trademark Office Biotechnology and Chemical Pharmaceutical
Customer Partnership is scheduled for Tuesday January 14, 2003 from 9:00
am to 4:30pm in Crystal Square 4 suite 700, located on 1745 Jefferson
Davis Highway in Arlington, Virginia.
Please contact Cecilia
Tsang at 703-308-0254 or by fax at 703-746-7144 or email Cecilia.Tsang@uspto.gov
or contact Sharlamar Taliaferro at 703-306-4094 or by fax 703-305-8002
or email Sharlamar.Taliaferro@uspto.gov
to decline or confirm your attendance.
Biotechnology/Chemical/Pharmaceutical
Customer Partnership
Tuesday,
January 14th, 2003
United States Patent and Trademark Office
Arlington, Virginia 22202
Crystal Square 4, 7th Floor, Room 1
Morning
Session |
9:00-9:15
AM |
Greetings
and Overview |
Jasemine
Chambers
John Doll
Bruce Kisliuk
Directors, TC 1600 |
9:15-9:30
AM |
“Official
Notice” taken in Office actions |
John
Doll |
9:30-10:15
AM |
Vector
Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities |
Deborah
Reynolds
Supervisory Patent Examiner Technology Center 1600 |
10:15-10:30
AM |
Break |
|
10:30-11:15
AM |
Sequence
Searches and Analysis |
Christopher
Low
Supervisory Patent Examiner Technology Center 1600 |
11:15
- 11:45 AM |
102
(e) and 102 (g) |
Rob
Clarke, OPLA |
11:45
AM -1:15 PM |
Lunch
Break |
|
Afternoon
Session |
1:15
- 2:00 PM |
Rule
132 Declarations and Unexpected Results |
Paula
Hutzell
Practice Specialist
Technology Center 1600 |
2:00
- 2:45 PM |
Non-Functional
Descriptive Material: 3-D Structures and Computer Algorithms |
Michael
Woodward
Supervisory Patent Examiner Technology Center 1600 |
2:45
- 3:00 PM |
Break |
|
3:00
- 4:00 PM |
Interpartes
Reexamination Changes |
Ken
Schor, OPLA |
4:00
- 4:15 PM |
Wrap
Up |
Jasemine
Chambers
John Doll
Bruce Kisliuk
Directors, TC 1600 |
|